XML 68 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisitions Preliminaty Purchase Price Allocation (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Sep. 26, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Goodwill $ 6,807.5   $ 5,749.0
Reata Pharmaceuticals, Inc      
Business Acquisition [Line Items]      
Cash and cash equivalents   $ 267.3  
Accounts receivable   15.9  
Inventory   1,692.0  
Other current assets   53.6  
Operating lease assets   122.4  
Accrued expense and other   (98.9)  
Debt payable   (159.9)  
Contingent payable to Blackstone(1)   (300.0)  
Deferred tax liability   (922.5)  
Operating lease liabilities   (151.8)  
Other assets and liabilities, net   (2.0)  
Total identifiable net assets   6,136.1  
Goodwill   1,057.3  
Total assets acquired and liabilities assumed   7,193.4  
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)      
Business Acquisition [Line Items]      
Intangible assets:   3,600.0  
Reata Pharmaceuticals, Inc | In-process research and development      
Business Acquisition [Line Items]      
Intangible assets:   1,900.0  
Reata Pharmaceuticals, Inc | Priority review voucher      
Business Acquisition [Line Items]      
Intangible assets:   100.0  
Reata Pharmaceuticals, Inc | Other clinical programs      
Business Acquisition [Line Items]      
Intangible assets:   $ 20.0